CompleGen and Berlex Biosciences have entered into an agreement whereby CompleGen is supplying Berlex with a high throughput assay system for discovery of compounds active against a novel target identified by Berlex. The target assay uses CompleGen's XenoGene system which identifies compounds that are specifically active against the target protein, but not other cellular components.

Under the terms of the agreement, Berlex has paid CompleGen a fee, with further terms and payments to be agreed if suitable compounds, identified during the project, are developed and commercialized.

CompleGen's Chief Scientific Officer, Dr. John Swindle, indicated that this is the second such agreement between CompleGen and Berlex and said, "We are very happy to be working with Berlex' Oncology Research group and their skilled compound screening team."